GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Radius Health Inc (NAS:RDUS) » Definitions » 5-Year RORE %

Radius Health (Radius Health) 5-Year RORE % : 0.00% (As of Jun. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Radius Health 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Radius Health's 5-Year RORE % for the quarter that ended in Jun. 2022 was 0.00%.

The industry rank for Radius Health's 5-Year RORE % or its related term are showing as below:

RDUS's 5-Year RORE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.595
* Ranked among companies with meaningful 5-Year RORE % only.

Radius Health 5-Year RORE % Historical Data

The historical data trend for Radius Health's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radius Health 5-Year RORE % Chart

Radius Health Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -10.71 3.95 1.82 -9.32 -24.73

Radius Health Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.61 -20.80 -24.73 -26.12 -28.51

Competitive Comparison of Radius Health's 5-Year RORE %

For the Drug Manufacturers - Specialty & Generic subindustry, Radius Health's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radius Health's 5-Year RORE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Radius Health's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Radius Health's 5-Year RORE % falls into.



Radius Health 5-Year RORE % Calculation

Radius Health's 5-Year RORE % for the quarter that ended in Jun. 2022 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -1.46--5.79 )/( -15.19-0 )
=4.33/-15.19
=-28.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2022 and 5-year before.


Radius Health  (NAS:RDUS) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Radius Health 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Radius Health's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Radius Health (Radius Health) Business Description

Traded in Other Exchanges
N/A
Address
22 Boston Wharf Road, 7th Floor, Boston, MA, USA, 02210
Radius Health Inc is an integrated biopharmaceutical company. It develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company's product, TYMLOS, is for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The product pipeline of the company includes Abaloparatide-patch for the treatment of postmenopausal women with osteoporosis, Elacestrant, and RAD140. It primarily operates the business in the United States of America and generates key revenue from the sales of TYMLOS.
Executives
Willard H Dere director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Jean Pierre Garnier director UNITED TECHNOLOGIES CORP, 10 FARM SPRINGS ROAD, FARMINGTON CT 06032
Von Eschenbach Andrew C. director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Jennifer Jarrett director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Cathy Friedman director C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
G. Kelly Martin director, officer: CEO and President C/O NOVAN, INC., 4105 HOPSON RD, MORRISVILLE NC 27560
Sean Murphy director C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703
Owen Hughes director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Elizabeth Messersmith officer: Senior Vice President 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210
Danielle Holtschlag officer: Vice President, Sales 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210
Chhaya Shah officer: Chief Business Officer 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210
Susan Vissers Lisa director 22 BOSTON WHARF ROAD 7TH FLOOR BOSTON MA 02210
Rubric Capital Management Lp 10 percent owner 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000

Radius Health (Radius Health) Headlines